HUE032158T2 - Eljárás delta9-THC-aminosav-észterek elõállítására - Google Patents

Eljárás delta9-THC-aminosav-észterek elõállítására Download PDF

Info

Publication number
HUE032158T2
HUE032158T2 HUE09824226A HUE09824226A HUE032158T2 HU E032158 T2 HUE032158 T2 HU E032158T2 HU E09824226 A HUE09824226 A HU E09824226A HU E09824226 A HUE09824226 A HU E09824226A HU E032158 T2 HUE032158 T2 HU E032158T2
Authority
HU
Hungary
Prior art keywords
thc
amino acid
osa osa
vol
prodrugs
Prior art date
Application number
HUE09824226A
Other languages
English (en)
Inventor
Mahmoud A Elsohly
Waseem Gul
Michael A Repka
Soumyajit Majumdar
Original Assignee
Univ Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mississippi filed Critical Univ Mississippi
Publication of HUE032158T2 publication Critical patent/HUE032158T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B13/00—Accessories or details of general applicability for machines or apparatus for cleaning
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B3/00—Cleaning by methods involving the use or presence of liquid or steam
    • B08B3/02—Cleaning by the force of jets or sprays
    • B08B3/026—Cleaning by making use of hand-held spray guns; Fluid preparations therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B08—CLEANING
    • B08B—CLEANING IN GENERAL; PREVENTION OF FOULING IN GENERAL
    • B08B2203/00—Details of cleaning machines or methods involving the use or presence of liquid or steam
    • B08B2203/02—Details of machines or methods for cleaning by the force of jets or sprays
    • B08B2203/0264—Splash guards

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)

Claims (5)

  1. Szabadalmi ígdnvpsMsmk î.
  2. Elprâs « kösmkezöképim# Δ^ΐ«ί?#κ^0^#Μΐ8ΐ>«>0Ηΐ»^ό§8ν·482^ vsgyílkd MMUMsIfa
    ahol R s jsfemése
    amely eljárás tartalmazza a köyeskezö tépéseket
    a kövefezS I. .reaksióváziat szerimi mixisxmrsl È ). ax: gaUaassv &amp;tH!4érmí$~s^í:8*a$#á8ák: vlíSáiiltásá, 2) . 8:<; íUsiiííösáv íiîïï 1--förîïîïáí~s:í:ároiágék&amp;íísk TBC-vél. valé rösgákaiáísá «a 3) »g aïîïlftosav TI:IC>yHi~fö^Ä*s2äriÄ^kI0ä|k: 2.: Eljárás a |öv«äke:aö .kép&amp;tö .á'f'Sarf&amp;EMrok:áKrsablra>l^al£EsíossV'-ésxísf vsgyßls* «IhálUsására
    ahoi H : jelerstéa®
    R2j elemese
    ahol R: és: a·: > msnmeKim úgy; eapesoensnak egym«;:mm; bogy égy pgpriaamesi ammaam a üoveíkeee I. réâkclûvaalal: arm l-ul méteen'sí
    aiOelv eljárás ta?TbP>aaza a kövéíkézb lépéseket: 1.):¾¾ smiíKssáv &amp;iii:l^fta^«iás-'SZánpaze&amp;á!:i3lv: ©töálilfása, 3):¾¾ âMiapsstv sslli“fonïkà!--»ïài'{î)8Kél;âïisk Tl-lC-vei való reagáftaíass, 3) az apünösák THC-ájlil.-íö^5áí-s2iárp>s2éká!sak &amp; vabiksopöRanasResRése, 4) a öiásödik aHsiíkisay aMcibrm iái szántstszékátiak Tliü-aRsiíKiSavval való f&amp;agákaiása ás 5) az ailRRbtebákszáikazák védöasöpákaPeísasSíáse, ásni a TBC' dk&amp;mmosaV'Szányaizékáí: afadakayezi,
  3. 3. Eljárás az alábbi képiéi# às^et'^ïhiàfpkâiuiab}.t5ol.--aïîî:iéôs&amp;v-észl:er vsgväki aiiklibissára ah©! R; jeiéstós
    jelentése
    R s jeteïîîésç
    ah«i a?. H s és R.;; maradékok-ès sa Rv es R:i ûg-y kapéàidôdï'ak «gya;«;:!w. hagy egy |íeptiiikő!áai a|ks>«nsk, •a. kővetkező i. reakciôvïiaiat sitesinu módszerrel
    Ms-ài jeilamwve, hogy tu dkhás tatfahn&amp;aiüiJi 3 kftvahoíö SêpeSahet: I is RK «mmosaS? îâl I i^ fï>î ï ïî s îîî --¾î îî 3:^4¾¾¾ âïaiï : éî^ai ! ííáss s M oh a i á è s r :k n ;ι«Ά à n » k TMCvd vaio Hsa?ákaíáss, .ï|:sâ sniissi't.áv ; MC-aHH-lonniát-az^Tmaiaékának a vediVsopon-'menttsftéés.. 4) s sogsodik #lí*Bh$1i:ÍBMS|Í8Sliil»9k s>gÿ TBCHlougosayvid vate ?ság4líátáMí: 3; δ.ί an:!í!*»áv a Ü is fonn ! át - s ϊát» ; &amp;?.éká v al kapcsok RiO-ammosav védöcsoport-meni«dí&amp;si8i· 6} s KäkdiSilsk «nriiiosav alH}-forRaidta>:&amp;nnaadkaiia\ ΓΗ<.-· di-an»oosa vval vak» rsagdtidásaés 7}a/aihMormrti-származék v^ddcsopon-waHvaiube, ami a HU' fri-a^igo-sav.^aàçmiKÈékât a:«dm«avö:ai.
  4. 4. Az I -3. igénypontok bármelyik« szermií djáíás. rand$ á)aaUM&amp;®: továbbá aâ,M, igéöypöiítok háilmdyikt; szerion A^^yay^lokimnsfHHril»^ vegyííid hemíszö&amp;vmáfjáAsk és hémlglmartysöak döál jitásal á^gytíidö^tsotl^yMkö.SSv^lliiáéWeí vagy"glmápMV-enhiáriddök báZisfcátdízátdf jdédiiéhë» végsői rébisdöjávab öiafd &amp; rgákciőkevsrék &amp;ál köbeié bssbásáv&amp;b
  5. 5. A 4v igénypont szerinti eljárás, ahol a háziskaOdiskor dímstüat8iói4#idin és tneliisrhin sevpréks;
HUE09824226A 2008-10-31 2009-11-02 Eljárás delta9-THC-aminosav-észterek elõállítására HUE032158T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11016508P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
HUE032158T2 true HUE032158T2 (hu) 2017-09-28

Family

ID=42129588

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09824226A HUE032158T2 (hu) 2008-10-31 2009-11-02 Eljárás delta9-THC-aminosav-észterek elõállítására

Country Status (11)

Country Link
US (2) US8809261B2 (hu)
EP (1) EP2352497B1 (hu)
JP (1) JP5739344B2 (hu)
AU (1) AU2009308665B2 (hu)
CA (1) CA2741862C (hu)
DK (1) DK2352497T3 (hu)
ES (1) ES2622582T3 (hu)
HK (1) HK1158517A1 (hu)
HU (1) HUE032158T2 (hu)
PL (1) PL2352497T3 (hu)
WO (1) WO2010051541A2 (hu)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160345631A1 (en) 2005-07-19 2016-12-01 James Monsees Portable devices for generating an inhalable vapor
US8991402B2 (en) 2007-12-18 2015-03-31 Pax Labs, Inc. Aerosol devices and methods for inhaling a substance and uses thereof
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
CA2788060C (en) 2010-03-17 2017-07-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
US10517530B2 (en) 2012-08-28 2019-12-31 Juul Labs, Inc. Methods and devices for delivering and monitoring of tobacco, nicotine, or other substances
EP3488847B1 (en) 2012-09-12 2023-11-08 Novaliq GmbH Semifluorinated alkane compositions
CN113679698B (zh) 2012-09-12 2022-07-26 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
US10279934B2 (en) 2013-03-15 2019-05-07 Juul Labs, Inc. Fillable vaporizer cartridge and method of filling
CN117137195A (zh) 2013-05-06 2023-12-01 尤尔实验室有限公司 用于气溶胶装置的烟碱盐调配物及其方法
CN105473012B (zh) 2013-06-14 2020-06-19 尤尔实验室有限公司 电子汽化设备中的具有单独的可汽化材料的多个加热元件
KR102328024B1 (ko) 2013-12-05 2021-11-17 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
USD842536S1 (en) 2016-07-28 2019-03-05 Juul Labs, Inc. Vaporizer cartridge
US20160366947A1 (en) 2013-12-23 2016-12-22 James Monsees Vaporizer apparatus
US10076139B2 (en) 2013-12-23 2018-09-18 Juul Labs, Inc. Vaporizer apparatus
USD825102S1 (en) 2016-07-28 2018-08-07 Juul Labs, Inc. Vaporizer device with cartridge
US10159282B2 (en) 2013-12-23 2018-12-25 Juul Labs, Inc. Cartridge for use with a vaporizer device
GB2558804B8 (en) 2013-12-23 2018-12-19 Juul Labs Uk Holdco Ltd Vaporization device systems and methods
US10058129B2 (en) 2013-12-23 2018-08-28 Juul Labs, Inc. Vaporization device systems and methods
WO2015175979A1 (en) 2014-05-16 2015-11-19 Pax Labs, Inc. Systems and methods for aerosolizing a smokeable material
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
AU2015280412B2 (en) 2014-06-26 2018-07-26 Island Breeze Systems Ca, Llc MDI related products and methods of use
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
MX2017007042A (es) 2014-12-05 2018-06-15 Juul Labs Inc Control de dosis calibrada.
EP3270896A4 (en) * 2015-03-19 2018-09-12 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
CN105037180B (zh) * 2015-04-19 2017-10-10 安徽省逸欣铭医药科技有限公司 一种双重作用的中枢性镇痛新化合物、制备方法及用途
EP3297617A4 (en) * 2015-05-18 2019-02-20 5071, Inc. HOMOGENEOUS CANNABIS COMPOSITIONS AND METHODS OF PRODUCING THE SAME
US20180007924A9 (en) 2015-05-18 2018-01-11 5071, Inc. Homogenous cannabis compositions and methods of making the same
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
CN110693825B (zh) 2015-09-30 2022-03-08 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
US10709681B2 (en) * 2016-01-29 2020-07-14 University Of Mississippi Biologically active cannabidiol analogs
DE202017007467U1 (de) 2016-02-11 2021-12-08 Juul Labs, Inc. Befüllbare Verdampferkartusche
SG10202108578XA (en) 2016-02-11 2021-09-29 Juul Labs Inc Securely attaching cartridges for vaporizer devices
US10405582B2 (en) 2016-03-10 2019-09-10 Pax Labs, Inc. Vaporization device with lip sensing
WO2017180954A1 (en) * 2016-04-15 2017-10-19 Ronald Silver Method of making cannabis oil hydrophiilic using emulsifiers and related cannabinoid compositions
JP7053054B2 (ja) 2016-04-15 2022-04-12 エスアールイー ウェルネス，インク． 大麻注入甘味料及び他の組成物
CN109476625A (zh) * 2016-06-16 2019-03-15 蒂温诺特技术有限公司 用于制备大麻素前药的方法、药物制剂及其用途
USD849996S1 (en) 2016-06-16 2019-05-28 Pax Labs, Inc. Vaporizer cartridge
USD848057S1 (en) 2016-06-23 2019-05-07 Pax Labs, Inc. Lid for a vaporizer
USD836541S1 (en) 2016-06-23 2018-12-25 Pax Labs, Inc. Charging device
USD851830S1 (en) 2016-06-23 2019-06-18 Pax Labs, Inc. Combined vaporizer tamp and pick tool
US11660403B2 (en) 2016-09-22 2023-05-30 Juul Labs, Inc. Leak-resistant vaporizer device
ES2965677T3 (es) 2016-09-23 2024-04-16 Novaliq Gmbh Composiciones oftálmicas que comprenden ciclosporina
CA3036313A1 (en) 2016-09-28 2018-04-05 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CA3059227A1 (en) 2017-04-05 2018-10-11 University Of Mississippi Isolation of pure cannabinoids from cannabis
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
EP3424493A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
EP3424494A1 (en) * 2017-07-07 2019-01-09 SolMic Research GmbH Stable cannabinoid compositions
CA3069694A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
WO2019045994A1 (en) * 2017-08-27 2019-03-07 Rhodes Technologies PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
USD887632S1 (en) 2017-09-14 2020-06-16 Pax Labs, Inc. Vaporizer cartridge
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
US11498018B2 (en) * 2017-11-27 2022-11-15 Vasilios (Bill) Panagiotakopoulos Extraction and purification of cannabinoid compounds
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物
WO2020097358A1 (en) * 2018-11-07 2020-05-14 Columbia Care, Llc Suppository formulations having cannabinoid
US20200254104A1 (en) * 2019-02-11 2020-08-13 John CHANCEY Methods of making and using phytocannabinoids complexed with a protein, peptide, amino acid, polysaccharide, disacchride, or monosaccharide
CA3132861A1 (en) * 2019-03-12 2020-09-17 6th Wave Innovations Corp. Molecularly imprinted polymers for extraction of cannabinoids and uses thereof
CA3136607A1 (en) * 2019-04-09 2020-10-15 Powderpost, Inc. Methods and compositions for use in treatment of cancer without psychoactive effects
US11242328B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Heterogeneous catalyst and method for preparation of aromatic tricyclic pyrans
US11242330B1 (en) 2021-02-25 2022-02-08 Acid Neutral Alkaline Laboratory Organic catalyst and method for preparation of aromatic tricyclic pyrans
US11352337B1 (en) * 2021-06-02 2022-06-07 Acid Neutral Alkaline Laboratory Zeolite catalyst and method for preparation of aromatic tricyclic pyrans

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB313977A (en) * 1927-12-21 1929-06-21 British United Shoe Machinery Improvements in or relating to boot or shoe sewing machines or methods of making boots or shoes by the use thereof
JPS5518709B2 (hu) 1970-02-13 1980-05-21
US4933363A (en) * 1988-08-16 1990-06-12 Elsohly Mahmoud A Method for effecting systemic delivery of delta-9-tetrahydrocannabinol
US6040298A (en) * 1992-12-23 2000-03-21 Oclassen Pharmaceuticals, Inc. Methods for treatment with compositions effective against acyclovir-resistant strains of herpes viruses
US5389375A (en) * 1993-05-21 1995-02-14 University Of Mississippi Stable suppository formulations effecting bioavailability of Δ9 -thc
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US6008383A (en) * 1998-10-26 1999-12-28 University Of Mississippi Method of preparing delta-9-tetrahydrocannabinol esters
US20060078955A1 (en) 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
JP2008522959A (ja) 2004-11-02 2008-07-03 シャイア エルエルシー 肝臓への送達を改善したリバビリンのプロドラッグ
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008134668A2 (en) 2007-04-27 2008-11-06 Alexza Pharmaceuticals, Inc. Heat-labile prodrugs
JP6073043B2 (ja) * 2007-08-21 2017-02-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 医薬品適用のための熱−動力学的混合
EP2211760A4 (en) * 2007-10-17 2013-09-18 Axxia Pharmaceuticals Llc POLYMER DRUG DELIVERY SYSTEMS AND METHODS OF EXTRUSION OF THERMOPLASTIC COMPOUNDS TO PRODUCE THESE SYSTEMS
DK2963031T3 (en) * 2007-11-30 2019-04-23 Zynerba Pharmaceuticals Inc PROGRESS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPREHENSIVE PRODRUG OF TETRAHYDROCANNABINOL AND METHODS FOR USING THE SAME
US20090169629A1 (en) * 2008-01-02 2009-07-02 Novagali Pharma Sa Micellar compositions with ophthalmic applications
EP2151234A1 (en) * 2008-07-28 2010-02-10 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
PL2352497T3 (pl) * 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc

Also Published As

Publication number Publication date
AU2009308665B2 (en) 2015-10-22
WO2010051541A2 (en) 2010-05-06
HK1158517A1 (zh) 2012-07-20
PL2352497T3 (pl) 2017-08-31
US20110275555A1 (en) 2011-11-10
EP2352497A2 (en) 2011-08-10
US20150045282A1 (en) 2015-02-12
ES2622582T3 (es) 2017-07-06
US8809261B2 (en) 2014-08-19
JP5739344B2 (ja) 2015-06-24
EP2352497A4 (en) 2012-08-01
WO2010051541A3 (en) 2010-07-08
DK2352497T3 (en) 2017-04-03
US9630941B2 (en) 2017-04-25
JP2012507568A (ja) 2012-03-29
CA2741862C (en) 2017-10-17
EP2352497B1 (en) 2017-02-22
AU2009308665A1 (en) 2010-05-06
CA2741862A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
DK2352497T3 (en) METHOD FOR PREPARING DELTA-9-THC AMINO ACID ESTERS
EP1299374B1 (en) Novel non-psychotropic cannabinoids
JP5372751B2 (ja) Ａｚａ−ペプチドプロテアーゼ阻害剤
US8614228B2 (en) Quinone prodrug compositions and methods of use
KR20170026633A (ko) Hiv-관련 장애의 치료 방법 및 치료용 조성물
US20170151225A1 (en) Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
FR2902100A1 (fr) Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
KR20060010839A (ko) 세로토닌 재흡수 저해제로서의 인돌 유도체
KR20060021896A (ko) 세로토닌 재흡수 저해제 형태의 인돌 유도체
US7235584B2 (en) Non-psychotropic cannabinoids
TW200301114A (en) Crystals of taxane derivative and process for the production thereof
CN110922450B (zh) Psma激活式抗肿瘤前药cpt-x及其制备方法和应用
JP4413427B2 (ja) ヌクレオシド
CN106496132B (zh) N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途
CN115260212B (zh) 3,5-双(亚苄基)-4-哌啶酮衍生物及其制备方法和应用
EP4037685B1 (en) Quinoline that modulate serca and its use for treating disease
CN114031561B (zh) 含4-苯氧基喹唑啉类化合物及其应用
CN113773259A (zh) 病毒主蛋白酶抑制剂及其制备方法和用途
Wilkerson et al. A bis-[N-3-(1-hydroxy-1-methyl-ethyl)-benzyl)-cyclic urea as a HIV protease inhibitor
WO2022049219A1 (en) Methods for treating viral infection
KR101881115B1 (ko) 신규 2-치환된 테트라하이드로피란 또는 2-치환된 테트라하이드로퓨란 유도체 화합물, 이의 제조방법 및 이의 용도
CN113620936A (zh) 一种吡咯烷类化合物及其应用
CN117384136A (zh) 一种no供体型抗真菌化合物及其制法和应用
WO2014029102A1 (zh) 噻嗪酰胺衍生物及其药物组合物和用途
CN115141136A (zh) 特考韦瑞药的共晶及其制备方法